US20130220871A1 - Method of providing pirfenidone therapy to a patient - Google Patents

Method of providing pirfenidone therapy to a patient Download PDF

Info

Publication number
US20130220871A1
US20130220871A1 US13861099 US201313861099A US2013220871A1 US 20130220871 A1 US20130220871 A1 US 20130220871A1 US 13861099 US13861099 US 13861099 US 201313861099 A US201313861099 A US 201313861099A US 2013220871 A1 US2013220871 A1 US 2013220871A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
day
pirfenidone
mg
dosage
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13861099
Inventor
Williamson Ziegler Bradford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InterMune Inc
Original Assignee
InterMune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035Blister-type containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00General identification or selection means
    • A61J2205/50General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Abstract

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application Ser. No. 60/870,593, filed Dec. 18, 2006, the disclosure of which is incorporated by reference in its entirety.
  • BACKGROUND
  • 1. Field of the Invention
  • The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.
  • 2. Description of the Related Art
  • Pirfenidone is small drug molecule whose chemical name is 5-methyl-1-phenyl-2-(1H)-pyridone. It is a non-peptide synthetic molecule with a molecular weight of 185.23 Daltons. Its chemical elements are expressed as C12H11NO, and its structure and synthesis are known. Pirfenidone is manufactured commercially and being evaluated clinically as a broad-spectrum anti-fibrotic drug. Several pirfenidone Investigational New Drug Applications (INDs) are currently on file with the U.S. Food and Drug Administration. Phase II human investigations are ongoing or have recently been completed for pulmonary fibrosis, renal glomerulosclerosis, and liver cirrhosis. There have been other Phase II studies that used pirfenidone to treat benign prostate hypertrophy, hypertrophic scarring (keloids), and rheumatoid arthritis.
  • Pirfenidone is being investigated for therapeutic benefits to patients suffering from fibrosis conditions such as Hermansky-Pudlak Syndrome (HPS) associated pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF). Pirfenidone is also being investigated for a pharmacologic ability to prevent or remove excessive scar tissue found in fibrosis associated with injured tissues including that of lungs, skin, joints, kidneys, prostate glands, and livers. Published and unpublished basic and clinical research suggests that pirfenidone may safely slow or inhibit the progressive enlargement of fibrotic lesions, and prevent formation of new fibrotic lesions following tissue injuries.
  • It is understood that one mechanism by which pirfenidone exerts its therapeutic effects is modulating cytokine actions. Pirfenidone is a potent inhibitor of fibrogenic cytokines and TNF-α. It is well documented that pirfenidone inhibits excessive biosynthesis or release of various fibrogenic cytokines such as TGF-β1, bFGF, PDGF, and EGF. Zhang Set al., Australian and New England J Ophthalmology 26:S74-S76 (1998). Experimental reports also show that pirfenidone blocks the synthesis and release of excessive amounts of TNF-α from macrophages and other cells. Cain et al., Int'l J Immunopharmacology 20:685-695 (1998).
  • As an investigational drug, pirfenidone is provided in tablet and capsule forms principally for oral administration. Various formulations have been tested and adopted in clinical trials and other research and experiments. The most common adverse reactions or events associated with pirfenidone therapy include gastrointestinal upset, nausea, fatigue, somnolence, dizziness, headache, and photosensitivity rash. Many of these effects can interfere with everyday activities and quality of life. These effects appear to be dose related. The adverse reactions associated with pirfenidone therapy are exacerbated when pirfenidone is administered at these higher doses.
  • Currently, adverse events following administration of pirfenidone are alleviated by dose reduction or discontinuation of pirfenidone. In a recent study, for adverse events rated Grade 2 or worse, the dosage was reduced in a stepwise manner: from 9 tablets having 200 mg of pirfenidone per day to 6 tablets having 200 mg of pirfenidone per day and 6 tablets having 200 mg of pirfenidone per day to 3 tablets having 200 mg of pirfenidone per day. Azuma, A. et al., Am J Respir Crit Care Med 171:1040-47 (2005) (“Azuma study”). More specifically, if, after a period of 14 days of observation with reduced dosage, the adverse event persisted or increased, the dosage was further reduced by one more step—from6 tablets per day to 3 tablets per day. If the adverse event persisted or increased despite reducing the dosage to 3 tablets per day, the study medication was discontinued.
  • The Azuma study discloses a dose-titration schedule for all patients wherein patients received a 200-mg dose of pirfenidone three times a day for the first two days; then a 400-mg dose of pirfenidone three times a day for the following two days; and then a maximum 600-mg dose of pirfenidone three times a day for the remainder of treatment. Thus, the maximum dose obtained by the Azuma study was only 1,800 mg/day of pirfenidone. Additionally, the dose-titration schedule of the Azuma study reaches the full maximum dosage of pirfenidone after only four days of treatment. There is significant reason to believe that the Azuma dose escalation does not optimally match the rate of dose escalation with the rate at which a patient develops sufficient tolerance to reduce the incidence of adverse events. Thus, there remains an unmet clinical need for a method of administering higher doses of pirfenidone to a patient in a manner that eliminates or minimizes adverse events, such as nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, somnolence, and other undesirable side effects.
  • SUMMARY
  • The present invention overcomes the unmet clinical need by providing an improved, optimized dose escalation scheme for the administration of pirfenidone. The dose escalation scheme of the present invention provides pirfenidone in an amount such that the full maximum dosage is not reached for at least one week. In a preferred embodiment, the full maximum dosage of pirfenidone is not reached until about Day 15 of treatment. The method of the present invention allows for a maximum dosage of 2,403 mg of pirfenidone per day to be administered to a patient and also reduces the incidence of adverse events associated with the administration of pirfenidone by more accurately matching dose escalation with tolerance development in the patient. Indeed, it has been observed that even as the dosage escalates using the dosing escalation scheme described herein, adverse events, such as somnolence, decrease.
  • The present invention discloses a method of providing pirfenidone therapy to a patient comprising providing an initial daily dosage of pirfenidone to the patient in a first amount for the duration of a first period of time; providing a second daily dosage of pirfenidone to the patient in a second amount for a second period of time; and providing a final daily dosage of pirfenidone to the patient in a final amount for a final period of time, wherein the first and second periods of time together total at least about 7 days, more preferably about 8, 9, 10, 11 or 12 days, and most preferably about 13 or 14 days. In some embodiments, the first and second periods can together total up to about 15 or about 20 or 21 days.
  • In one embodiment, the first amount is about 801 mg/day; the second amount is about 1,602 mg/day; and the third amount is about 2,403 mg/day. In another embodiment, the first period of time is about 7 days; the second period of time is about 7 days; and the third period of time is in the range of about 1 day up to an unlimited number of days. In specific embodiments, the third period of time lasts at least about 1 month, at least about 2 months, at least about 3 months, at least about a year, at least about 18 months, at least about 2 years, or more than 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or as long as therapy with pirfenidone is needed.
  • The present invention also discloses a starter pack comprising dosage amounts of pirfenidone and compartments that separate the dosage amounts according to a daily dosage of pirfenidone. Advantageously, the compartments can be arranged in columns and in rows, although other arrangements are also contemplated.
  • In one exemplary embodiment, the starter pack comprises rows designating Day numbers and separate columns for the number of times a dosage of pirfenidone is taken each day. In one embodiment, the starter pack may comprise separate rows for Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 with three separate columns for three dosage amounts to be taken each day. In one embodiment, each of the three compartments for Days 1, 2, 3, 4, 5, 6, and 7 separately contain one pill of 267-mg pirfenidone and each of the three compartments for Days 8, 9, 10, 11, 12, 13, and 14 separately contain two pills of 267-mg pirfenidone. In another embodiment, each week of treatment may be designated on a separate panel. In another embodiment, each panel contained within the starter pack may be approximately the same size. In another embodiment, the starter pack has compartments arranged such that a user of the starter pack may administer the pirfenidone in accordance with the dose escalation method taught by the present invention.
  • Also contemplated is use of pirfenidone in preparation of a medicament for the treatment of a fibrosis condition comprising administration of pirfenidone according to a dosing regimen as disclosed herein.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a structure of a portion of a starter pack for the first week of treatment.
  • FIG. 2 shows a structure of a portion of a starter pack for the second week of treatment.
  • FIG. 3 shows a structure of a portion of a starter pack for the third week of treatment.
  • FIG. 4 shows a starter pack having multiple panels that are folded.
  • FIG. 5 shows a starter pack having multiple panels in an unfolded position.
  • FIG. 6 shows another structure of a portion of a starter pack for the first week of treatment.
  • FIG. 7 shows another structure of a portion of a starter pack for the second week of treatment.
  • FIG. 8 shows another structure of a portion of a starter pack for the third week of treatment.
  • FIG. 9 shows a starter pack having a casing material holding three different containers in such a manner that a user can easily slide a container out of the casing material.
  • FIG. 10 shows a starter pack wherein a container is partially pulled out from the casing material.
  • FIG. 11 shows a container comprising a panel having a plurality of compartments for containing a dosage amount of pirfenidone.
  • FIG. 12 shows a container wherein the panel has been pulled outside of the container.
  • FIG. 13 shows a starter pack having a casing material holding at least one circular panel containing pirfenidone.
  • FIG. 14 shows another structure of a portion of a circular starter pack for the first week of treatment.
  • FIG. 15 shows another structure of a portion of a circular starter pack for the second week of treatment.
  • FIG. 16 shows another structure of a portion of a circular starter pack for the third week of treatment.
  • DETAILED DESCRIPTION
  • The present invention discloses a method of providing pirfenidone therapy to a patient with an escalating dosage regimen that mitigates adverse events associated with the use of pirfenidone and, it is believed, better matches the development of tolerance to potentially adverse effects of the drug with increases in the dosage. In one embodiment of the present invention is a method of providing pirfenidone therapy to a patient comprising providing an initial daily dosage of pirfenidone to the patient in a first amount for the duration of a first period of time; providing a second daily dosage of pirfenidone to the patient in a second amount for a second period of time; and providing a final daily dosage of pirfenidone to the patient in a final amount for a final period of time. The sum of the first and second periods of time is preferably at least about 7 days, more preferably about 8, 9, 10, 11, or 12 days, and most preferably about 13 or 14 days. In some embodiments, the first and second periods can together total up to about 15 or about 20 or 21 days. Although it is also contemplated that the first and second periods together can total more than 21 days, and can (for example) be 22, 24, 26, or 30 days, it is believed that the longer dose escalation periods are less than optimal, due to the decrease in therapeutic benefit to the patient resulting from the delay in administering the full therapeutic dosage.
  • Although the present disclosure exemplifies dose escalation regimens having three steps, it is also possible to have more steps in the same amount of time, so that the dosage escalates in smaller steps. Indeed, if desired, each dose can be incrementally larger than the previous dose, or the dose can escalate every day, every two days, or every three or four days, for example. Regardless of the dose escalation step size, the use of an initial dose and an ending dose in the amounts discussed below is particularly preferred.
  • In one embodiment, the first amount is in the range of about 400 mg/day to about 1,200 g/day. In another embodiment, the first amount is in the range of about 700 mg/day to about 900 mg/day. In another embodiment, the first amount is in the range of about 780 mg/day to about 820 mg/day. In another embodiment, the first amount is about 801 mg/day.
  • In one embodiment, the second amount is in the range of about 1,200 mg/day to about 2,000 mg/day. In another embodiment, the second amount is in the range of about 1,500 mg/day to about 1,700 mg/day. In another embodiment, the second amount is in the range of about 1,580 mg/day to about 1,620 mg/day. In another embodiment, the second amount is about 1,602 mg/day.
  • In one embodiment, the third amount is in the range of about 2,000 mg/day to about 3,000 mg/day. In another embodiment, the third amount is in the range of about 2,300 mg/day to about 2,400 mg/day. In another embodiment, the third amount is in the range of about 2,380 mg/day to about 2,420 mg/day. In another embodiment, the third amount is about 2,403 mg/day.
  • In one embodiment, the first period of time is in the range of about 3 days to about 10 days. In another embodiment, the first period of time is about 6 to about 8 days. In another embodiment, the first period of time is about 7 days.
  • In one embodiment, the second period of time is in the range of about 3 days to about 10 days. In another embodiment, the second period of time is about 6 to about 8 days. In another embodiment, the second period of time is about 7 days.
  • In one embodiment, the final period of time is in the range of about 1 day to an unlimited number of days. Preferably, the final period of time will be however long the duration of treatment with pirfenidone should last.
  • In one embodiment of the present invention is a method of providing pirfenidone therapy to a patient comprising providing an initial daily dosage of pirfenidone to the patient in an amount of 801 mg/day over the course of Day 1 to Day 7; providing a second daily dosage of pirfenidone to the patient in an amount of 1602 mg/day over the course of Day 8 to Day 14; and providing a final daily dosage of pirfenidone to the patient in an amount of 2403 mg/day on the beginning of Day 15 and continuing with the 2403 mg/day dosage on each day following Day 15.
  • In one embodiment, the patient is administered one capsule (a sub-daily dosage) comprising 267-mg of pirfenidone three times a day over the course of Day 1 to Day 7, to provide a daily dosage of 801 mg pirfenidone; then the patient is administered two capsules (a sub-daily dosage) comprising 267-mg of pirfenidone three times a day over the course of Day 8 to Day 14, to provide a daily dosage of 1602 mg pirfenidone; and then the patient is administered three capsules (a sub-daily dosage) comprising 267-mg of pirfenidone three times a day on Day 15 and each day thereafter, to provide a daily dosage of 2403 mg pirfenidone where the therapy continues after Day 15.
  • In one embodiment, a dosage amount of pirfenidone is taken with food. In another embodiment, the patient is instructed to administer the dosage of pirfenidone with food.
  • In another embodiment of the present invention, there is provided a starter pack comprising pirfenidone. Starter packs are a relatively easy method for singulating, transporting, storing and finally dispensing oral solid drugs. Such packs include, for instance, a planar transparent piece of plastic provided with “blisters” or convex protrusions configured in rows and columns. Each of the blisters or convex protrusions is sized to receive a singulated dosage amount of the particular oral solid drug being dispensed.
  • Typically, at least one backing layer is fastened to a solid receiving side of the blister pack. This layer is a low strength retaining barrier. This low strength retaining layer stretches across the backs of the blisters and retains the singulated oral dosage amounts individually sealed within each of the blisters.
  • Dispensing of drugs from such blister packs is easy to understand. The consumer presses down on a blister from the convex side of the blister. Such pressure bears directly against the singulated oral dosage amount contained in the blister. The singulated oral solid drug is then forced through the low strength retaining barrier. This low strength retaining barrier at least partially tears and breaks away. During this partial breaking and tearing away, the singulated oral dosage amount is partially—but typically not totally—ejected from its individual blister. Preferably, it is during this partial ejection that the oral solid drug is grasped by the user and consumed as directed. The result is a safe, sterile dispensing of the drug in desired single dosage amounts from the blister pack.
  • The starter pack of the present invention may comprise various dosage amounts of pirfenidone designated within blisters or other individual compartments so that the patient will take the proper dosage amount of the drug each day. The starter pack may comprise many different forms. One embodiment of the starter pack is shown in FIGS. 1-3. FIG. 1 shows a portion of a starter pack comprising dosage amounts for the first week of therapy using pirfenidone. The starter pack (10) for the first week of treatment may comprise a panel (12) having a plurality of compartments (16) for containing a dosage amount (18) of pirfenidone. The compartments (16) may be arranged in column and row fashion as illustrated, although other arrangements are also contemplated, including having all of the compartments arranged in a line, or having them arranged in a circular fashion. In an embodiment where the starter pack comprises columns and rows, each daily dosage may be represented in a singular row or a singular column.
  • FIG. 2 shows a portion of a starter pack comprising dosage amounts for the second week of therapy using pirfenidone. The starter pack (20) for the second week of treatment may comprise a panel (22) having a plurality of compartments (26) for containing a dosage amount (28) of pirfenidone. The compartments (26) for the second week of treatment may be fashioned to hold a greater amount of pirfenidone than the compartments (16) for the first week of treatment. The dosage amount (28) of pirfenidone for the second week may be greater than the dosage amount (18) of the first week.
  • FIG. 3 shows a portion of a starter pack comprising dosage amounts for the third week of therapy using pirfenidone. The starter pack (30) for the third week of treatment may comprise a panel (32) having a plurality of compartments (36) for containing a dosage amount (38) of pirfenidone. The compartments (36) for the third week of treatment may be fashioned to hold a greater amount of pirfenidone than the compartments (26) for the second week of treatment. The dosage amount (38) of pirfenidone for the third week may be greater than the dosage amount (28) of the second week.
  • Although FIGS. 1-3 show a starter pack wherein a panel represents one week of dosages, it is contemplated that a panel may be constructed to comprise more or less compartments. For instance, a panel may be constructed to hold dosage amounts for three days of treatment. In another embodiment, a panel may be constructed to hold dosage amounts for six days of treatment. In another embodiment, a panel may be constructed to hold dosage amounts for ten days of treatment. Any number of days and dosages in a single panel are contemplated by the inventors. Preferably, the starter pack may be designed so that the user administers pirfenidone according to the dose escalation scheme of the present invention.
  • In one embodiment, the starter pack comprises panels giving dosage amounts of pirfenidone for the first week of treatment and the second week of treatment. In another embodiment, the starter pack further comprises a panel giving dosage amounts of pirfenidone for the third week of treatment. In another embodiment, the starter pack comprises a panel or an insert that gives instructions to a patient for administering the proper dosage amount of pirfenidone.
  • In one embodiment, the starter pack may comprise only dosage amounts for the first week of treatment and the second week of treatment. Preferably, such a starter pack may also comprise instructions to the patient for administering the pirfenidone from a bottle for therapy after dose escalation is completed. It is contemplated that the user of the starter pack will continue therapy with pirfenidone pills from a bottle after dose escalation is completed.
  • The size of the starter pack and the panels that comprise the starter pack may be typical of similar starter packs already known. In a preferred embodiment, each panel within a starter pack is approximately of similar size dimensions as the other panels of the starter pack.
  • In some embodiments, the starter pack comprises a unitary structure, wherein the unitary structure comprises more than one panel and each panel may comprise dosage amounts for one week of treatment. In some embodiments, the starter pack comprises a panel that has printed instructions thereon. FIG. 4 shows a starter pack (40) having multiple panels (42, 44, 46) that are folded. The starter pack has at least one region (48) capable of folding so that the separate panels (42, 44, 46) can be stacked upon one another while the starter pack (40) maintains its unitary structure. In some embodiments, the starter pack may comprise panels (42, 44) having compartments for containing dosages of pirfenidone. The dosages may be pushed through the low strength retaining barrier at points (45) opposite the location of the blisters.
  • FIG. 5 shows a fully unfolded starter pack (50) comprising four panels (52, 54, 56, 58). The Week 1 panel (54) may have compartments (54 a) that comprise a dosage amount (54b) of pirfenidone related to the first week of treatment. The Week 2 panel (56) may have compartments (56 a) that comprise a dosage amount (56 b) of pirfenidone related to the second week of treatment. Optionally, a panel for the dosage amounts of Week 3 may be included. The Week 3 panel (58) may have compartments (58 a) that comprise a dosage amount (58 b) of pirfenidone related to the third week of usage. The other panel (52) may be left blank or provided with instructions or any other type of indicia. In some embodiments, the starter pack (50) may comprise an adhesive seal or a sticker that holds the starter pack in folded form until the adhesive seal or sticker is broken by a user. The starter pack may comprise regions (55) capable of folding so that the separate panels (52, 54, 56, 58) can be stacked upon one another while the starter pack (50) maintains its unitary structure.
  • In one embodiment, one panel (54) may comprise compartments (54 a) giving the dosage amount (54 b) for Days 1-7 of the dose escalation scheme and the second panel (56) may comprise compartments (56 a) giving the dosage amount (56 b) for Days 8-14 of the dose escalation scheme. In another embodiment, an optional third panel (58) may be further provided to comprise compartments (58 a) giving the dosage amount (58 b) for Days 15-21 of the dose escalation scheme.
  • FIG. 6 shows a portion of another starter pack comprising dosage amounts for the first week of therapy using pirfenidone. The starter pack (60) for the first week of treatment may comprise a panel (62) having a plurality of compartments (66) for containing a dosage amount (68) of pirfenidone. The compartments (66) may be arranged in column and row fashion as illustrated, although other arrangements are also contemplated, including having all of the compartments arranged in a line, or having them arranged in a circular fashion. Additionally, instructions may be provided on the starter pack (60) indicating the proper day and time the dosage amount (68) should be administered.
  • FIG. 7 shows a portion of another starter pack comprising dosage amounts for the second week of therapy using pirfenidone. The starter pack (70) for the second week of treatment may comprise a panel (72) having a plurality of compartments (76) for containing a dosage amount (78) of pirfenidone. The compartments (76) for the second week of treatment may be fashioned to hold a greater amount of pirfenidone than the compartments (66) for the first week of treatment. The dosage amount (78) of pirfenidone for the second week may be greater than the dosage amount (68) of the first week. Additionally, instructions may be provided on the starter pack (70) indicating the proper day and time the dosage amount (78) should be administered.
  • FIG. 8 shows a portion of another starter pack comprising dosage amounts for the third week of therapy using pirfenidone. The starter pack (80) for the third week of treatment may comprise a panel (82) having a plurality of compartments (86) for containing a dosage amount (88) of pirfenidone. The compartments (86) for the third week of treatment may be fashioned to hold a greater amount of pirfenidone than the compartments (76) for the second week of treatment. The dosage amount (88) of pirfenidone for the third week may be greater than the dosage amount (78) of the second week. Additionally, instructions may be provided on the starter pack (80) indicating the proper day and time the dosage amount (88) should be administered.
  • In some embodiments, the starter pack may comprise a casing material that holds separate panels, wherein at least one panel comprises a plurality of compartments for containing a dosage amount of pirfenidone. In some embodiments, the panel may be located within a container having flat outer surfaces so that the container may easily be slid in and out of the casing material. FIG. 9 shows a starter pack (90) having a casing material (98) holding three different containers (92, 94, 96) in such a manner that a user can easily slide a container out of the casing material (98). In one embodiment, each container may comprise a panel that comprises a plurality of compartments that hold a dosage amount of pirfenidone. In some embodiments, the panels may further comprise instructions or indicia so that a user can administer pirfenidone according to the dose escalation scheme. In some embodiments, a panel may be provided separately for providing indicia or instructions on using the drug. In some embodiments, indicia or instructions may be provided on one or more of the containers (92, 94, 96).
  • FIG. 10 shows a starter pack (100) comprising a casing material (108) and at least one container (102). The container (102) is partially pulled out from the casing material ( )8) and may comprise a panel having a plurality of compartments for containing a dosage amount of pirfenidone. For example, the container (102) may comprise any of the panels shown in FIGS. 1-3 and FIGS. 6-8. Preferably, each panel will be approximately the same size for easy and compact insertion into the casing material (108).
  • FIG. 11 shows a container (110) comprising a panel (112) having a plurality of compartments (116) for containing a dosage amount (118) of pirfenidone. The panel (112) is partially pulled out from the container (110) and can be slid in and out for easy use. FIG. 12 shows a container (120) wherein the panel (122) having a plurality of compartments (126) for containing a dosage amount (128) of pirfenidone has been completely pulled from the container (120). Instructions may be provided on a separate sheet (124) within the container (120) in addition to the panel (122). Alternatively, instructions or other indicia may be printed directly on the container (120) or the panel (122).
  • One embodiment of the present invention is a starter pack comprising dosage amounts of pirfenidone and compartments that separate the dosage amounts according to a daily dosage of pirfenidone. In one embodiment, the starter pack comprises a row designating Day numbers and separate columns for the number of times a dosage of pirfenidone is taken each day. In one embodiment, the starter pack may comprise separate rows for Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 with three separate columns for three dosage amounts to be taken each day. In one embodiment, each of the three compartments for Days 1, 2, 3, 4, 5, 6, and 7 separately contain one pill of 267-mg pirfenidone and each of the three compartments for Days 8, 9, 10, 11, 12, 13, and 14 separately contain two pills of 267-mg pirfenidone. In another embodiment, each week of treatment may be designated on a separate panel. In another embodiment, each panel contained within the starter pack may be approximately the same size. In another embodiment, the starter pack has compartments arranged such that a user of the starter pack will administer the pirfenidone in accordance with the dose escalation method taught by the present invention.
  • In one embodiment, the starter pack further comprises additional rows for Days 15, 16, 17, 18, 19, 20, and 21. In another embodiment, each of the three compartments corresponding to Days 15, 16, 17, 18, 19, 20, and 21 separately contain three pills of 267-mg pirfenidone. The addition of the rows for Days 15, 16, 17, 18, 19, 20, and 21 is for the purpose of training the patient as to the correct amount of dosage that will be needed after the starter pack is finished and the patient begins taking pills from another source, such as a pill bottle. By providing the starter pack with a third week at the full dosage of pirfenidone, the patient will be better accustomed to taking the 2,403 mg/day dosage from Day 15 and each Day thereafter as required by the pirfenidone therapy method of the present invention.
  • In another embodiment, the starter pack comprises a circular form. FIG. 13 shows a container (130) comprising a base (138) that holds at least one panel (132) having a plurality of compartments (136) for containing a dosage amount of pirfenidone. The panel (132) is circular in shape with compartments (136) extending in a radial pattern from the center and wherein each radius designates its own Day for treatment with pirfenidone. The dosages for AM, noon, and PM may be separated in a manner shown in FIG. 13. The container (130) also comprises a lid (139) so that at least one panel (132) containing pirfenidone can be stored within the container (130) and sealed.
  • FIG. 14 shows a portion of a starter pack comprising dosage amounts for the first week of therapy using pirfenidone. The starter pack (140) for the first week of treatment may comprise a circular panel (142) having a plurality of compartments (146) for containing a dosage amount (148) of pirfenidone. The compartments (146) may be arranged so that they extend radially from the center of the pane (142). The panel (142) may comprise indicia informing the patient which dosage to administer at the appropriate time.
  • FIG. 15 shows a portion of a starter pack comprising dosage amounts for the second week of therapy using pirfenidone. The starter pack (110) for the second week of treatment may comprise a circular panel (152) having a plurality of compartments (156) for containing a dosage amount (118) of pirfenidone. The compartments (156) may be arranged so that they extend radially from the center or so that they fit within a panel. The panel (152) may comprise indicia informing the patient which dosage to administer at the appropriate time.
  • FIG. 16 shows a portion of a starter pack comprising dosage amounts for the third week of therapy using pirfenidone. The panel for the third week of therapy is optionally provided. The starter pack (160) for the third week of treatment may comprise a circular panel (162) having a plurality of compartments (166) for containing a dosage amount (168) of pirfenidone. The compartments (146) may be arranged so that they extend radially from the center of the pane (162). The panel (162) may comprise indicia informing the patient which dosage to administer at the appropriate time.
  • In another embodiment, the starter pack has compartments arranged such that a user of the starter pack will administer the pirfenidone in accordance with the dose escalation method taught by the present invention. Of course, as an alternative to blister packs, the doses can be contained in any other type of compartment, such as plastic bags or other containers fastened together in book form; plastic containers with snap-open lids arranged in a row or other geometric pattern, or any of a wide variety of other dosage-containing packages.
  • In one embodiment, a method for administering pirfenidone therapy to a patient comprises initially administering a predetermined starting dosage of pirfenidone to the patient and escalating the dosage administered to the patient over a predetermined time to a predetermined full dosage of pirfenidone. In some embodiments, the predetermined time is measured from the initial starting dosage and is between about 7 and 20 days. In some embodiments, the predetermined time is 13 or 14 days. In some embodiments, the starting dosage is about 801 mg/day. In some embodiments, the full dosage is about 2,403 mg/day. In some embodiments, the dosages are split into three daily oral administrations.
  • The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be falling within the scope of the invention.

Claims (46)

    What is claimed:
  1. 1. A method of providing pirfenidone therapy to a patient comprising:
    providing a first daily dosage of pirfenidone to the patient in a first amount for the duration of a first period of time;
    providing a second daily dosage of pirfenidone to the patient in a second amount for a second period of time; and
    providing a third daily dosage of pirfenidone to the patient in a third amount for a third period of time, wherein the first and second periods of time total at least about 7 days.
  2. 2. The method according to claim 1, wherein the first amount is in the range of about 400 mg/day to about 1,200 mg/day.
  3. 3. The method according to claim 2, wherein the first amount is in the range of about 700 mg/day to about 900 mg/day.
  4. 4. The method according to claim 3, wherein the first amount is in the range of about 780 mg/day to about 820 mg/day.
  5. 5. The method according to claim 4, wherein the first amount is about 801 mg/day.
  6. 6. The method according to claim 1, wherein the second amount is in the range of about 1,200 mg/day to about 2,000 mg/day.
  7. 7. The method according to claim 6, wherein the second amount is in the range of about 1,500 mg/day to about 1,700 mg/day.
  8. 8. The method according to claim 7, wherein the second amount is in the range of about 1,580 mg/day to about 1,620 mg/day.
  9. 9. The method according to claim 8, wherein the second amount is about 1,602 mg/day.
  10. 10. The method according to claim 1, wherein the third amount is in the range of about 2,000 mg/day to about 3,000 mg/day.
  11. 11. The method according to claim 10, wherein the third amount is in the range of about 2,300 mg/day to about 2,400 mg/day.
  12. 12. The method according to claim 11, wherein the third amount is in the range of about 2,380 mg/day to about 2,420 mg/day.
  13. 13. The method according to claim 12, wherein the third amount is about 2,403 mg/day.
  14. 14. The method according to claim 1, wherein the first period of time is in the range of about 3 days to about 10 days.
  15. 15. The method according to claim 14, wherein the first period of time is about 7 days.
  16. 16. The method according to claim 1, wherein the second period of time is in the range of about 3 days to about 10 days.
  17. 17. The method according to claim 16, wherein the second period of time is about 7 days.
  18. 18. The method according to claim 1, wherein the third period of time is at least one day.
  19. 19. The method according to claim 18, wherein the third period of time is more than one day.
  20. 20. A method of providing pirfenidone therapy to a patient comprising:
    providing a first daily dosage of pirfenidone to the patient in an amount of 801 mg/day over the course of Day 1 to Day 7;
    providing a second daily dosage of pirfenidone to the patient in an amount of 1602 mg/day over the course of Day 8 to Day 14; and
    providing a third daily dosage of pirfenidone to the patient in an amount of 2403 mg/day on the beginning of Day 15 and continuing with the 2403 mg/day dosage on each day following Day 15.
  21. 21. The method according to claim 20,
    wherein the patient is administered one capsule comprising 267-mg of pirfenidone three times a day over the course of Day 1 to Day 7;
    wherein the patient is administered two capsules comprising 267-mg of pirfenidone three times a day over the course of Day 8 to Day 14; and
    wherein the patient is administered three capsules comprising 267-mg of pirfenidone three times a day on Day 15 and each day thereafter where the therapy continues after Day 15.
  22. 22. A starter pack comprising:
    a first set of compartments each having a first dosage amount of pirfenidone according to a first daily or first sub-daily periodic dosage of pirfenidone;and
    at least one additional set of compartments each having a dosage amount of pirfenidone that is higher than the first dosage amount of pirfenidone and is according to a higher daily or higher sub-daily periodic dosage of pirfenidone.
  23. 23. The starter pack according to claim 22, wherein the starter pack comprises a row for each Day that the first daily periodic dosage is to be taken and for each Day that the higher daily periodic dosage is to be taken and separate columns for each of the first sub-daily periodic dosage to be taken and for each of the higher sub-daily periodic dosage to be taken, and wherein the first out of compartments are arranged within the rows and columns, and wherein the at least one additional set of compartments is arranged within the rows and columns.
  24. 24. The starter pack according to claim 23, wherein the first set of compartments and the at least one additional set of compartments each comprise three columns for each Day pirfenidone is to be taken.
  25. 25. The starter pack according to claim 24, wherein the starter pack comprises separate rows for Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.
  26. 26. The starter pack according to claim 25, wherein the first set of compartments are for administering the first dosage amount of pirfenidone for Days 1, 2, 3, 4, 5, 6, and 7, and each compartment in the first set of compartments contains one pill of 267-mg pirfenidone.
  27. 27. The starter pack according to claim 25, wherein the at least one additional set of compartments comprises a second set of compartments for administering a second dosage amount of pirfenidone higher than the first dosage amount and for Days 8, 9, 10, 11, 12, 13, and 14, and each compartment in the second set of compartments contains two pills of 267-mg pirfenidone.
  28. 28. The starter pack according to claim 27, wherein the starter pack comprises separate rows for Days 15, 16, 17, 18, 19, 20, and 21.
  29. 29. The starter pack according to claim 28, wherein the at least one additional set of compartments comprises a third set of compartments for administering a third dosage amount of pirfenidone higher than the second dosage amount and for Days 15, 16, 17, 18, 19, 20, and 21, and each compartment in the third set of compartments contains three pills of 267-mg pirfenidone.
  30. 30. The starter pack according to claim 22, further comprising a first panel having the first set of compartments and an additional panel for each of the at least one additional set of compartments, each of the first and additional panels containing an equal number of compartments
  31. 31. The starter pack according to claim 22, wherein the compartments are blisters.
  32. 32. The starter pack according to claim 22, wherein the starter pack comprises at least two panels and at least one fold separating the two panels, and wherein a first panel comprises dosage amount for a first period of time and wherein a second panel comprises dosage amounts for a second period of time.
  33. 33. The starter pack of claim 22, further comprising a casing for holding several containers each container comprising a panel bearing one of the first set of compartments or one of the at least one additional set of compartments.
  34. 34. A starter pack comprising:
    an initial dosage amount, a second dosage amount, and a third dosage amount of pirfenidone; and
    a plurality of compartments that separate the initial, second, and third dosage amounts according to a daily dosage of pirfenidone,
    wherein the compartments are formed in columns and in rows; and the compartments are arranged in such a manner that a user of the starter pack is instructed to take the pirfenidone in accordance with the method disclosed by claim 21.
  35. 35. A method for administering pirfenidone therapy to a patient, comprising:
    administering a predetermined first daily dosage of pirfenidone to the patient; and
    escalating the dosage administered to the patient to a predetermined final daily dosage of pirfenidone, wherein the time of escalation is measured from the initial first dosage and is about 7 to about 20 days.
  36. 36. The method of claim 35, wherein the time of escalation is 13 or 14 days.
  37. 37. The method of claim 36, wherein the first dosage is about 801 mg/day.
  38. 38. The method of claim 37, wherein the final dosage is about 2,403 mg/day.
  39. 39. The method of claim 38, wherein each daily dosage is split into three daily oral administrations.
  40. 40. A starter pack comprising:
    a first panel having a plurality of compartments each providing a first daily dosage of pirfenidone for a patient in a first amount for the duration of a first period of time;
    a second panel having a plurality of compartments each providing a second daily dosage of pirfenidone for the patient in a second amount for a second period of time; and
    a third panel having a plurality of compartments each providing a third daily dosage of pirfenidone for the patient in a third amount for a third period of time, wherein the first and second periods of time each total at least about 7 days.
  41. 41. The starter pack according to claim 40, wherein the first daily dosage is in the range of about 700 mg/day to about 900 mg/day.
  42. 42. The starter pack according to claim 40, wherein the second daily dosage is in the range of about 1,500 mg/day to about 1,700 mg/day.
  43. 43. The starter pack according to claim 40, wherein the third daily dosage is in the range of about 2,300 mg/day to about 2,400 mg/day.
  44. 44. The starter pack according to claim 40, wherein the first period of time is in the range of about 3 days to about 10 days.
  45. 45. The starter pack according to claim 40, wherein the second period of time is in the range of about 3 days to about 10 days.
  46. 46. The starter pack according to claim 40, wherein the third period of time is more than one day.
US13861099 2006-12-18 2013-04-11 Method of providing pirfenidone therapy to a patient Abandoned US20130220871A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US87059306 true 2006-12-18 2006-12-18
US11959338 US7767700B2 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient
US12831944 US8420674B2 (en) 2006-12-18 2010-07-07 Method of providing pirfenidone therapy to a patient
US13861099 US20130220871A1 (en) 2006-12-18 2013-04-11 Method of providing pirfenidone therapy to a patient

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13861099 US20130220871A1 (en) 2006-12-18 2013-04-11 Method of providing pirfenidone therapy to a patient
US15212674 US20160324842A1 (en) 2006-12-18 2016-07-18 Method of providing pirfenidone therapy to a patient
US15874590 US20180140588A1 (en) 2006-12-18 2018-01-18 Method of Providing Pirfenidone Therapy to a Patient

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12831944 Continuation US8420674B2 (en) 2006-12-18 2010-07-07 Method of providing pirfenidone therapy to a patient

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15212674 Continuation US20160324842A1 (en) 2006-12-18 2016-07-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
US20130220871A1 true true US20130220871A1 (en) 2013-08-29

Family

ID=39259551

Family Applications (6)

Application Number Title Priority Date Filing Date
US11959338 Active 2029-04-01 US7767700B2 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient
US12427532 Active US7696236B2 (en) 2006-12-18 2009-04-21 Method of providing pirfenidone therapy to a patient
US12831944 Active 2028-11-02 US8420674B2 (en) 2006-12-18 2010-07-07 Method of providing pirfenidone therapy to a patient
US13861099 Abandoned US20130220871A1 (en) 2006-12-18 2013-04-11 Method of providing pirfenidone therapy to a patient
US15212674 Abandoned US20160324842A1 (en) 2006-12-18 2016-07-18 Method of providing pirfenidone therapy to a patient
US15874590 Abandoned US20180140588A1 (en) 2006-12-18 2018-01-18 Method of Providing Pirfenidone Therapy to a Patient

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11959338 Active 2029-04-01 US7767700B2 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient
US12427532 Active US7696236B2 (en) 2006-12-18 2009-04-21 Method of providing pirfenidone therapy to a patient
US12831944 Active 2028-11-02 US8420674B2 (en) 2006-12-18 2010-07-07 Method of providing pirfenidone therapy to a patient

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15212674 Abandoned US20160324842A1 (en) 2006-12-18 2016-07-18 Method of providing pirfenidone therapy to a patient
US15874590 Abandoned US20180140588A1 (en) 2006-12-18 2018-01-18 Method of Providing Pirfenidone Therapy to a Patient

Country Status (8)

Country Link
US (6) US7767700B2 (en)
EP (4) EP2471534A1 (en)
JP (1) JP2010513320A (en)
CA (1) CA2667654C (en)
DE (1) DE602007014113D1 (en)
DK (1) DK2124945T3 (en)
ES (2) ES2395396T3 (en)
WO (1) WO2008077068A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471534A1 (en) 2006-12-18 2012-07-04 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
CA2936330A1 (en) 2014-01-10 2015-07-16 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
JP4077320B2 (en) * 2001-01-29 2008-04-16 塩野義製薬株式会社 5-methyl-1-phenyl-2-(1h) - pharmaceutical formulations containing pyridone as an active ingredient
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
CA2496577A1 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
US20070172446A1 (en) * 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
WO2005040758A3 (en) * 2003-10-24 2005-09-29 Lawrence M Blatt Use of pirfenidone in therapeutic regimens
US20090148407A1 (en) * 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
CN101484167B (en) * 2006-06-15 2012-07-04 上海睿星基因技术有限公司 The use of derviate of pyridone for preventing and treating radioactive injury of lungs
KR20090024834A (en) * 2006-07-05 2009-03-09 어레이 바이오파마 인크. Novel inhibitors of hepatitis c virus replication
EP2471534A1 (en) 2006-12-18 2012-07-04 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2008144720A3 (en) * 2007-05-21 2009-01-08 Univ Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241873B2 (en) 2013-07-03 2016-01-26 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD747602S1 (en) 2013-10-07 2016-01-19 Abbvie Inc. Template for a prescription medicine container
USD748392S1 (en) 2013-10-07 2016-02-02 Abbvie Inc. Template for a prescription medicine container
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD747091S1 (en) 2014-04-16 2016-01-12 Abbvie Inc. Template for a prescription medicine container

Also Published As

Publication number Publication date Type
US20080194644A1 (en) 2008-08-14 application
WO2008077068A1 (en) 2008-06-26 application
CA2667654A1 (en) 2008-06-26 application
DE602007014113D1 (en) 2011-06-01 grant
EP2471534A1 (en) 2012-07-04 application
ES2581844T3 (en) 2016-09-07 grant
US7767700B2 (en) 2010-08-03 grant
EP2124945A1 (en) 2009-12-02 application
ES2395396T3 (en) 2013-02-12 grant
EP2124945B1 (en) 2011-04-20 grant
CA2667654C (en) 2016-12-13 grant
US8420674B2 (en) 2013-04-16 grant
DK2124945T3 (en) 2011-08-01 grant
US20160324842A1 (en) 2016-11-10 application
EP3053580A1 (en) 2016-08-10 application
EP2338489A1 (en) 2011-06-29 application
US20090197923A1 (en) 2009-08-06 application
US7696236B2 (en) 2010-04-13 grant
US20180140588A1 (en) 2018-05-24 application
US20100324097A1 (en) 2010-12-23 application
EP2338489B1 (en) 2016-04-27 grant
JP2010513320A (en) 2010-04-30 application

Similar Documents

Publication Publication Date Title
US8415401B2 (en) Oral pharmaceutical dosage forms
US6077530A (en) Analgesic dosage units for coordinated administration
US6651816B2 (en) Antihistamine/decongestant regimens for treating rhinitis
US5850919A (en) Compliance closure
US6941948B2 (en) Medicament storage and delivery devices
Matheson et al. Racecadotril
Mavissakalian et al. Imipramine dose-response relationship in panic disorder with agoraphobia: preliminary findings
US20100021539A1 (en) Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation
Bassil et al. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease
US20080110792A1 (en) Methods for administering weight loss medications
US20020066691A1 (en) Therapy pack
US7150355B2 (en) Case with pill receiving sleeves for storing and dispensing pills
Beaver Impact of non-narcotic oral analgesics on pain management
US20080167343A1 (en) Methods and compositions using cholinesterase inhibitors
WO2002044180A1 (en) Lactam compounds and medicinal use thereof
WO2008009476A2 (en) Concentrated methotrexate solutions
US7422110B2 (en) Titration/compliance pack with increasing doses
US20050053648A1 (en) Medication delivery device
Bigal et al. The triptan formulations: a critical evaluation
WO2005039580A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
US20060034913A1 (en) Multiplex drug delivery device
US20090163551A1 (en) Compositions and Methods for Treating Diseases
WO2008046014A1 (en) Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
Moore Pain management in dental practice: tramadol vs. codeine combinations
US20070015728A1 (en) Metered-dose and safety and compliance packaging for systemic anticancer therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERMUNE, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRADFORD, WILLIAMSON ZIEGLER;REEL/FRAME:037933/0249

Effective date: 20070213

AS Assignment

Owner name: INTERMUNE, INC., CALIFORNIA

Free format text: CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS;ASSIGNOR:INTERMUNE, INC.;REEL/FRAME:046638/0466

Effective date: 20180711